



## **Quanta Announces Poster Presentation at ASN Kidney Week 2019**

**Alcester, Warwickshire, UK, 04 November 2019:** Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a pioneering British medical technology company developing a personal haemodialysis system (SC+) for patient use at home and in the clinic, announces that the Company will be presenting a poster at the ASN conference, reporting on results from an experimental pulsatile push–pull flow mechanism. These results demonstrate feasibility of using a small and easy-to-use haemodialysis system like SC+ to deliver enhanced solute clearance comparable to hemodiafiltration without any added complexity. The American Society of Nephrology (ASN) Kidney Week 2019 is being held November 5–10, 2019, in Washington DC.

### **Poster Presentation:**

**Title:** Enhancement of Solute Clearance Using Experimental Pulsatile Push–Pull Dialysate Flow for the Quanta SC+: A Personal Clinic-to-Home Haemodialysis System

**Abstract:** SA-PO1076

**Session:** Home Hemodialysis

**Location:** Exhibit Hall, Walter E. Washington Convention Center

**Date & Time:** Saturday, 9<sup>th</sup> November 2019, 10:00 a.m. – 12:00 p.m. ET

The full poster will be available to view after the presentation on Quanta’s website: [www.quantadt.com](http://www.quantadt.com)

If you would like to arrange a meeting with John E. Milad, Chief Executive Officer or Dr. Paul Komenda, Chief Medical Officer, please contact [enquiries@quantadt.com](mailto:enquiries@quantadt.com)

**-ENDS-**

### **For more information about Quanta, please contact:**

#### **Quanta**

John E. Milad,  
Chief Executive Officer

T: +44 (0)1789 400043  
E: [enquiries@quantadt.com](mailto:enquiries@quantadt.com)

#### **Consilium Strategic Communications**

Amber Fennell / Matthew Neal / Lindsey Neville

T: +44 (0)203 709 5708  
E: [quanta@consilium-comms.com](mailto:quanta@consilium-comms.com)

### **About SC+**

SC+ is a small, simple and powerful haemodialysis system designed to provide greater flexibility around where, when and how patients manage and receive their dialysis therapy. As a CE marked medical device, SC+ has been successfully piloted with the NHS, demonstrating clinical efficacy and performance compatible with traditional treatment regimens used in-centre. The innovative and patented technology behind SC+ is based on a design breakthrough that allows all dialysate fluid management to be conducted on a small, lightweight, disposable cartridge. The small form factor and simple-to-use design are intended to enable a broader range of users—including patients themselves—to manage dialysis therapy delivery across a wide range of settings—from the clinic to the home.

### **About Quanta**

UK-based Quanta Dialysis Technologies aims to improve the lives of dialysis patients through innovation. Quanta's lead product SC+ is designed to empower dialysis patients by giving them greater flexibility, convenience and control over the delivery of their life-sustaining renal replacement therapy. The company has attracted funding from a group of leading investors that includes Wellington Partners, Seroba Life Sciences and b-to-v Partners.

For more information, please visit: [www.quantadt.com](http://www.quantadt.com)